A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Active:	No
Cancer Type:	Unknown Primary	NCT ID:	NCT05673876
Trial Phases:	Phase I	Protocol IDs:	GA43861 (primary) NCI-2023-00306 ISRCTN27200385
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Genentech Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05673876

Summary

The primary purpose of the study is to assess the safety and pharmacokinetics (PK) of
GDC-8264 in participants with acute graft-versus-host disease (aGVHD).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.